Kenneth N. Raymond, Ph.D.
President and Chairman

Professor Raymond is a Lumiphore founder having received a B.A. from Reed College and a Ph.D. in Chemistry from Northwestern University. He began his appointment at the University of California, Berkeley in 1967, where he is currently Chancellor’s Professor of Chemistry and has served as Chair of the Chemistry Department. He is a Faculty Senior Scientist of the Chemical Sciences Division, Lawrence Berkeley National Laboratory and has been a Visiting Professor or Lecturer at several universities around the world. His research group in recent years has averaged twenty postdoctoral fellows and Ph.D. students, with an annual budget of approximately $1 million. Among his major awards are the Ernest O. Lawrence Award of the Department of Energy, a Humboldt Research Award for Senior U.S. Scientists, the American Chemical Society Alfred Bader Award in Bioinorganic or Bioorganic Chemistry, and the 2008 ACS Award in Inorganic Chemistry. He is a member of the National Academy of Sciences and the American Academy of Arts and Sciences. Professor Raymond is a member of the editorial boards of several journals in the fields of inorganic and bioinorganic chemistry and is the author of many patents and research publications. He has been a consultant for DuPont Corp. (transition metal imaging agents), Monsanto Corp. (Roundup®, – phosphonomethylglycine), Epix Corp. (gadolinium MRI agents) and LJL Corp. (high-throughput screening). He was the first member of the scientific advisory board for Salutar, which produced Omniscan®, an MRI agent in wide clinical use. Professor Raymond also serves as Co-Chair of Lumiphore’s Scientific Advisory Board.

 Darren Magda, Ph.D.
Vice President, Research and Development

Dr. Magda has a B.S. degree in Chemistry and completed his Ph.D. degree at the University of Texas with Professor Jonathan Sessler. Following a postdoctoral appointment at the California Institute of Technology he joined Pharmacyclics, a pharmaceutical company based in Sunnyvale, CA. From 1998 to 2009 he was Director of Exploratory Research at Pharmacyclics. Dr. Magda’s expertise in the laboratory ranges most aspects of preclinical chemistry and biology, with emphasis on developing metal complexes for use in medicine. Among other professional societies, he is a member of the Radiation Research Society and American Association for Cancer Research. Dr. Magda manages much of the laboratory work associated with our on-going projects and assists Dr. Blose in developing partnering opportunities for Lumiphore technology.

Nathaniel G. Butlin, Ph.D.
Chief Scientific Consultant

Dr. Butlin received his B.S. In Chemistry from McGill University, (Montreal, Canada) and his Ph.D. from the University of California – Davis following work in the labs of Professor Claude F. Meares and Professor G. Tayhas R. Palmore. Dr. Butlin has received DOE (GATE) and NSF (IGERT) fellowships for work on metallo-protein fuel-cell catalyst engineering as well as a NSF (GK-12) education fellowship. His recent protein engineering work with Professor Meares was focused on development of pretargeted strategies for cancer therapy, analytical methods for proteomics, and antibody expression. Dr. Butlin brings knowledge and skills related to protein conjugation chemistry, immunoassay development, bioelectronic interfacing, lanthanide chelation chemistry, and bioanalytical methods to the Lumiphore team. Dr. Butlin has been co-inventor and author on multiple patents and papers related to applied protein engineering and currently serves as Co-Chair of Lumiphore’s Scientific Advisory Board.

Stephen H. Blose, Ph.D.
Chief Business Development Officer

Following his doctoral training in molecular biology and medicine at the University of Pennsylvania, Mr. Blose joined Cold Spring Harbor Laboratory as a Senior Scientist working for Nobel Laureate Dr. James D. Watson in cancer research. He then joined Protein Databases, Inc. (PDI), eventually becoming the CEO, and, during his tenure, developed significant relationships with Millipore, Pharmacia LKB Biotechnology (now GE Healthcare) and Toyobo Co., Ltd. PDI was acquired by Bio-Rad Laboratories Inc., a $1.2-billion company, and Mr. Blose became General Manager of their Imaging Products Division. Under his leadership the division achieved 15-20% annual growth, becoming one of the most rapidly growing Bio-Rad business segments. He later founded the Mill Valley Summit Group, LLC, a transaction advisory group, that successfully helped early stage companies in life science products and medical devices raise more than $45-million from venture financing, licensing deals, and asset transactions. Mr. Blose is Chairman of the Board at BioMicro Systems Inc., Board Director and Board Secretary of Sentrx Animal Care, Inc., and, he is regarded as a founder of the proteomics industry.


Kenneth N. Raymond, Ph.D.

See above.

Marco Beckmann

Marco Beckmann is founder and CEO of Nanostart AG, a German venture capital company that is focused on nanotechnology investments. Beckmann is one of Europe’s leading experts in the field of nanotechnology and investments. He has published three books on the subject of nanotechnology investing including, “Nanostocks – Aktien der Zukunft” (“Nanostocks – Shares for the Future”, 2001) and “Profitieren von Nanotechnologie” (“Profiting from Nanotechnology”, 2002). Beckmann began his professional career as a sub-adviser at the Hauck & Aufhäuser DAC Nanotech Fund, an internationally invested equity fund specializing in nanotechnology. Beckmann holds the position of managing director of VentureTech Equity-Partners GmbH and Chairman of the supervisory board of the exchange-listed German nanotechnology company, ItN Nanovation AG (Saarbrücken, Germany). Through his pioneering work, Beckmann has been one of the first to seriously explore the implications of nanotechnology for the global capital markets. As the author of numerous articles and columns in international journals, Beckmann has helped to guide balanced and objective discussions about the potential of this extremely promising new technology. Nanostart AG is the primary investor in Lumiphore’s Series A financing.

David J. Ecker, Ph.D.

Dr. Ecker is co-founder of Isis Pharmaceuticals and Founder of the Ibis Biosciences where he is currently Chief Scientific Officer. Dr. Ecker was instrumental in the development of the Ibis T5000 (formerly TIGER) program for infection control, infectious disease diagnostics, biological weapons defense sponsored by DARPA, CDC, NIAID, FBI and DHS. Prior to Isis, Dr. Ecker was Assistant Director, Department of Molecular Genetics at SmithKline and French Laboratories (SK&F). While at SK&F, he focused on applications of molecular biology to drug discovery. Dr. Ecker contributed to a number of SK&F therapeutic programs including cancer, arthritis/inflammation, antiviral, and antifungal. He also designed and supervised the SK&F oligonucleotide synthesis facility. Dr. Ecker has published extensively in fields that include biodefense technology development, chemistry, DNA synthesis, gene construction and expression, protein structure and function, enzymology, and gene regulation. He has authored more than 100 scientific publications and issued more than 50 U.S. patents. Dr. Ecker received his Ph.D. in chemistry and biochemistry from Utah State University and was an American Cancer Society Fellow in chemistry at the University of California, Berkeley. He brings considerable expertise to Lumiphore including patent management, business development, strategic direction and the management of corporate and government partnerships from his over 25 years of experience in the pharmaceutical/biotechnology.


Jonathan L. Sessler, Ph.D.

Professor Sessler is a founding member of Lumiphore’s Scientific Advisory Board. He received a B.S. degree (with highest honors) in chemistry from the University of California, Berkeley and a Ph.D. in organic chemistry from Stanford University. Following postdoctoral studies in France and Japan, he joined the faculty at the University of Texas at Austin, where he is the Roland K. Pettit Professor of Chemistry. He is an expert in the area of synthetic porphyrins or analogs and the applications of this chemistry to metals in medicine. He has authored more than 300 research publications, one book, and nearly sixty issued or allowed U.S. patents. He is a co-founder of Pharmacyclics, Inc., a publicly traded company (PCYC; NASDQ) developing biomedical applications of expanded porphyrins. He recently co-founded Anionics, Inc. (anion recognition chemistry). Professor Sessler serves as Editor of Supramolecular Chemistry and as Associate Editor for Porphyrins and Phthalocyanines. Some of his honors include President’s Associates Teaching Excellence Award, Arthur C. Cope Scholar Award, Alexander von Humboldt Senior Visiting Scientist, Fellow of the American Association for the Advancement of Science, and the Izatt-Christensen Award in Macrocyclic Chemistry.

Thomas J. Meade, Ph.D.

Professor Meade is the Eileen M. Foell Professor of Chemistry, Biochemistry and Molecular and Cell Biology, Neurobiology and Physiology and Radiology at Northwestern University and is a world leader in molecular imaging research. He is an expert coordination chemist, with his primary biotech contribution in the area of magnetic resonance imaging (MRI) probe development. Professor Meade’s research focuses on the design, synthesis and physical properties of transition metal and lanthanide coordination complexes, specifically in the areas of biological molecular imaging, electron transfer mechanisms and metal complexes enzyme inhibitors. Professor Meade has founded four successful start-up companies based on his research at the California Institute of Technology and Northwestern University including Clinical Micro Sensors (CMS) which is developing electrochemical sensors for the detection of nucleic acids and was acquired by Motorola in 2000 for $300 million, Metaprobe and PreDx both focused on imaging technologies, and Ohmx, a biosensor detection company. Profesor Meade is currently the inventor on more than 70 patents and patent applications and many academic research publications.

Larry Mimms, Ph.D.

Dr. Mimms received his Ph.D. in biochemistry from Duke University and was a NIH Postdoctoral Fellow at Harvard University in Cellular and Developmental Biology prior to joining Abbott Laboratories in the Hepatitis/AIDS Business Unit. Dr. Mimms brings considerable experience to Lumiphore from his time in the diagnostics industry serving in executive positions at both Abbott Laboratories and Gen-Probe. Dr. Mimms led the team at Gen-Probe which won the 2004 National Medal of Technology for development and commercialization of new blood testing technologies and systems for the direct detection of viral diseases. His expertise spans immunoassay and molecular diagnostic research, product development, strategic planning and business development and clinical and regulatory issues. Dr. Mimms is currently a member of Tech Coast Angels and serves as a consultant to many biotech companies including startups and publically traded enterprises. Dr. Mimms recently founded VDx LLC to develop and market rapid, point of care HIV diagnostic tests.